Cargando…
Case Report: Lymphocytosis Associated With Fatal Hepatitis in a Thymoma Patient Treated With Anti-PD1: New Insight Into the Immune-Related Storm
Recent advances in tumor immunotherapy have made it possible to efficiently unleash immune effectors, reacting against neoplastic cells. Although these approaches primarily aim to eradicate malignancy, immune-related adverse events (irAEs) often influence patients’ prognosis, constituting a new spec...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768075/ https://www.ncbi.nlm.nih.gov/pubmed/33381454 http://dx.doi.org/10.3389/fonc.2020.583781 |
_version_ | 1783629098291036160 |
---|---|
author | Argentiero, Antonella Solimando, Antonio Giovanni Ungaro, Valentina Laforgia, Mariarita Strippoli, Sabino Pinto, Dario Negri, Antonio Ferraiuolo, Simona Zito, Alfredo Guida, Michele |
author_facet | Argentiero, Antonella Solimando, Antonio Giovanni Ungaro, Valentina Laforgia, Mariarita Strippoli, Sabino Pinto, Dario Negri, Antonio Ferraiuolo, Simona Zito, Alfredo Guida, Michele |
author_sort | Argentiero, Antonella |
collection | PubMed |
description | Recent advances in tumor immunotherapy have made it possible to efficiently unleash immune effectors, reacting against neoplastic cells. Although these approaches primarily aim to eradicate malignancy, immune-related adverse events (irAEs) often influence patients’ prognosis, constituting a new spectrum of side effects. Taking into account the typical microenvironment and the intricate equilibrium between the anti-tumor response and the immune cells, the thymoma constitutes a unicum in the immune-oncology field. We report a fatal immune-mediated adverse events’ storm in a thymoma patient treated with Pembrolizumab, leading to hepatotoxicity accompanied by lymphocytosis, thrombocytopenia, and thyroid dysfunction, unveiling a novel potential pathophysiological effect of immunotherapy. The clinical proficiency of the immune checkpoint inhibitors in thymoma patients warrants timely prevention and management of off-target consequences in order to optimize this promising therapeutic option. This case report describes a unique consequence of irAEs, emerging as a red flag warranting a multidisciplinary approach. |
format | Online Article Text |
id | pubmed-7768075 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-77680752020-12-29 Case Report: Lymphocytosis Associated With Fatal Hepatitis in a Thymoma Patient Treated With Anti-PD1: New Insight Into the Immune-Related Storm Argentiero, Antonella Solimando, Antonio Giovanni Ungaro, Valentina Laforgia, Mariarita Strippoli, Sabino Pinto, Dario Negri, Antonio Ferraiuolo, Simona Zito, Alfredo Guida, Michele Front Oncol Oncology Recent advances in tumor immunotherapy have made it possible to efficiently unleash immune effectors, reacting against neoplastic cells. Although these approaches primarily aim to eradicate malignancy, immune-related adverse events (irAEs) often influence patients’ prognosis, constituting a new spectrum of side effects. Taking into account the typical microenvironment and the intricate equilibrium between the anti-tumor response and the immune cells, the thymoma constitutes a unicum in the immune-oncology field. We report a fatal immune-mediated adverse events’ storm in a thymoma patient treated with Pembrolizumab, leading to hepatotoxicity accompanied by lymphocytosis, thrombocytopenia, and thyroid dysfunction, unveiling a novel potential pathophysiological effect of immunotherapy. The clinical proficiency of the immune checkpoint inhibitors in thymoma patients warrants timely prevention and management of off-target consequences in order to optimize this promising therapeutic option. This case report describes a unique consequence of irAEs, emerging as a red flag warranting a multidisciplinary approach. Frontiers Media S.A. 2020-12-14 /pmc/articles/PMC7768075/ /pubmed/33381454 http://dx.doi.org/10.3389/fonc.2020.583781 Text en Copyright © 2020 Argentiero, Solimando, Ungaro, Laforgia, Strippoli, Pinto, Negri, Ferraiuolo, Zito and Guida http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Argentiero, Antonella Solimando, Antonio Giovanni Ungaro, Valentina Laforgia, Mariarita Strippoli, Sabino Pinto, Dario Negri, Antonio Ferraiuolo, Simona Zito, Alfredo Guida, Michele Case Report: Lymphocytosis Associated With Fatal Hepatitis in a Thymoma Patient Treated With Anti-PD1: New Insight Into the Immune-Related Storm |
title | Case Report: Lymphocytosis Associated With Fatal Hepatitis in a Thymoma Patient Treated With Anti-PD1: New Insight Into the Immune-Related Storm |
title_full | Case Report: Lymphocytosis Associated With Fatal Hepatitis in a Thymoma Patient Treated With Anti-PD1: New Insight Into the Immune-Related Storm |
title_fullStr | Case Report: Lymphocytosis Associated With Fatal Hepatitis in a Thymoma Patient Treated With Anti-PD1: New Insight Into the Immune-Related Storm |
title_full_unstemmed | Case Report: Lymphocytosis Associated With Fatal Hepatitis in a Thymoma Patient Treated With Anti-PD1: New Insight Into the Immune-Related Storm |
title_short | Case Report: Lymphocytosis Associated With Fatal Hepatitis in a Thymoma Patient Treated With Anti-PD1: New Insight Into the Immune-Related Storm |
title_sort | case report: lymphocytosis associated with fatal hepatitis in a thymoma patient treated with anti-pd1: new insight into the immune-related storm |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768075/ https://www.ncbi.nlm.nih.gov/pubmed/33381454 http://dx.doi.org/10.3389/fonc.2020.583781 |
work_keys_str_mv | AT argentieroantonella casereportlymphocytosisassociatedwithfatalhepatitisinathymomapatienttreatedwithantipd1newinsightintotheimmunerelatedstorm AT solimandoantoniogiovanni casereportlymphocytosisassociatedwithfatalhepatitisinathymomapatienttreatedwithantipd1newinsightintotheimmunerelatedstorm AT ungarovalentina casereportlymphocytosisassociatedwithfatalhepatitisinathymomapatienttreatedwithantipd1newinsightintotheimmunerelatedstorm AT laforgiamariarita casereportlymphocytosisassociatedwithfatalhepatitisinathymomapatienttreatedwithantipd1newinsightintotheimmunerelatedstorm AT strippolisabino casereportlymphocytosisassociatedwithfatalhepatitisinathymomapatienttreatedwithantipd1newinsightintotheimmunerelatedstorm AT pintodario casereportlymphocytosisassociatedwithfatalhepatitisinathymomapatienttreatedwithantipd1newinsightintotheimmunerelatedstorm AT negriantonio casereportlymphocytosisassociatedwithfatalhepatitisinathymomapatienttreatedwithantipd1newinsightintotheimmunerelatedstorm AT ferraiuolosimona casereportlymphocytosisassociatedwithfatalhepatitisinathymomapatienttreatedwithantipd1newinsightintotheimmunerelatedstorm AT zitoalfredo casereportlymphocytosisassociatedwithfatalhepatitisinathymomapatienttreatedwithantipd1newinsightintotheimmunerelatedstorm AT guidamichele casereportlymphocytosisassociatedwithfatalhepatitisinathymomapatienttreatedwithantipd1newinsightintotheimmunerelatedstorm |